Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$2.75B |
| 2 |
Coupang
CPNG
|
$1.09B |
| 3 |
Trade Desk
TTD
|
$793M |
| 4 |
BioNTech
BNTX
|
$736M |
| 5 |
Bilibili
BILI
|
$639M |
Top Sells
| 1 |
Tesla
TSLA
|
$7.41B |
| 2 |
Alphabet (Google) Class C
GOOG
|
$1.39B |
| 3 |
Meta Platforms (Facebook)
META
|
$880M |
| 4 |
Amazon
AMZN
|
$773M |
| 5 |
NIO
NIO
|
$619M |
Sector Composition
| 1 | Consumer Discretionary | 31.93% |
| 2 | Healthcare | 19.13% |
| 3 | Technology | 17.13% |
| 4 | Communication Services | 14.58% |
| 5 | Financials | 5.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Regeneron Pharmaceuticals
REGN
$60.1B
| $30K | ﹤0.01% |
63
+3
| +5% | +$1.43K |
|
302
Monolithic Power Systems
MPWR
$40.6B
| $29K | ﹤0.01% |
83
+4
| +5% | +$1.4K |
|
|
BLUE
303
DELISTED
bluebird bio
BLUE
| $28K | ﹤0.01% |
70
-1,731
| -96% | -$692K |
|
304
Amdocs
DOX
$9.31B
| $28K | ﹤0.01% |
+400
| New | +$28K |
|
305
Medifast
MED
$152M
| $28K | ﹤0.01% |
+134
| New | +$28K |
|
306
Trimble
TRMB
$19B
| $28K | ﹤0.01% |
359
+13
| +4% | +$1.01K |
|
|
INFN
307
DELISTED
Infinera Corporation Common Stock
INFN
| $28K | ﹤0.01% |
2,941
+99
| +3% | +$943 |
|
|
AYX
308
DELISTED
Alteryx, Inc.
AYX
| $28K | ﹤0.01% |
336
+15
| +5% | +$1.25K |
|
309
InMode
INMD
$911M
| $27K | ﹤0.01% |
738
+46
| +7% | +$1.68K |
|
310
Insmed
INSM
$30.1B
| $27K | ﹤0.01% |
787
+27
| +4% | +$926 |
|
|
EGOV
311
DELISTED
NIC Inc
EGOV
| $27K | ﹤0.01% |
+800
| New | +$27K |
|
312
BlackBerry
BB
$2.26B
| $26K | ﹤0.01% |
3,082
-93
| -3% | -$785 |
|
313
Coherus Oncology, Inc. Common Stock
CHRS
$152M
| $26K | ﹤0.01% |
1,807
+104
| +6% | +$1.5K |
|
314
CrowdStrike
CRWD
$104B
| $25K | ﹤0.01% |
138
+6
| +5% | +$1.09K |
|
315
PagerDuty
PD
$1.55B
| $25K | ﹤0.01% |
615
+9
| +1% | +$366 |
|
316
Vuzix
VUZI
$171M
| $25K | ﹤0.01% |
+1,000
| New | +$25K |
|
317
CommScope
COMM
$3.6B
| $24K | ﹤0.01% |
1,543
+57
| +4% | +$887 |
|
318
Exponent
EXPO
$3.69B
| $24K | ﹤0.01% |
242
-1
| -0.4% | -$99 |
|
319
Keysight
KEYS
$28.7B
| $24K | ﹤0.01% |
169
+12
| +8% | +$1.7K |
|
320
Cohen & Steers
CNS
$3.71B
| $23K | ﹤0.01% |
356
+12
| +3% | +$775 |
|
321
Dropbox
DBX
$7.94B
| $23K | ﹤0.01% |
881
-42
| -5% | -$1.1K |
|
|
SMAR
322
DELISTED
Smartsheet Inc.
SMAR
| $23K | ﹤0.01% |
353
+27
| +8% | +$1.76K |
|
323
Avery Dennison
AVY
$13B
| $22K | ﹤0.01% |
118
+9
| +8% | +$1.68K |
|
324
Box
BOX
$4.74B
| $22K | ﹤0.01% |
979
-36
| -4% | -$809 |
|
325
Fiverr
FVRR
$864M
| $22K | ﹤0.01% |
+100
| New | +$22K |
|